Polymorphic xenobiotic compound

From the bulk of publications and preceding sections in this and other chapters of this book, it is apparent that it may be useful to build an integrated computational approach that will (i) predict which transporters will have affinity for novel xenobiotic compounds, (ii) identify whether the role of one or more human transporters (and their polymorphisms) may be a risk factor for patients and drug developers, (iii) propose potential toxic effects, and (iv) enable the combination of predicted and experimental data (gene expression, in vitro biology, etc.) for drug transporters (Figure 14.6). 

---